Developer docs
API playgroundTry for free, no card

Search company profiles

DEKA Research & Development

Full company profile

uuid003geuo

Namestring
DEKA Research & Development
Legal namestring
DEKA Research & Development Corp.
Company typeenum
Private
Founded yearint
1982
Descriptiontext

DEKA Research & Development Corp. is a privately held, founder-led medical technology development company founded in 1982 by inventor Dean Kamen and headquartered in Manchester, New Hampshire. The company employs nearly 1,000 engineers, technicians, machinists, and designers who develop life-changing medical devices, with a portfolio exceeding 6,000 patents. Its core technical competency is fluidics, which it applies across infusion systems, subcutaneous drug delivery pumps, and on-site medical-grade water production.

DEKA's product portfolio spans multiple medical domains: drug delivery (twiist Automated Insulin Delivery System, Remunity pump for Remodulin, microneedle applicators, SAFEflow infusion controller), home dialysis systems (Amia, Kaguya, HemoCare), mobility solutions (iBOT 3000 and iBOT PMD stair-climbing wheelchairs, LUKE robotic arm), water purification (Slingshot), and autonomous robotics (SENTRY). The company has also spun off notable inventions into separate ventures, including the Segway and the Coke Freestyle beverage dispenser.

DEKA's business model combines three revenue streams: licensing of proprietary technology to established healthcare and pharmaceutical partners, contract R&D services for partners such as Baxter and ARMI, and direct manufacturing of select devices. Distribution is achieved primarily through OEM/embedded partnerships rather than direct sales — most notably with Baxter/Vantive for dialysis, Mobius Mobility and 2Kerr for the iBOT, and pharmaceutical partners for insulin and Remodulin delivery systems. Founder Dean Kamen retains full ownership and operational control of the company, which has remained private since founding.

Short descriptiontext

DEKA Research & Development is a privately held, founder-led medical technology developer founded in 1982 by Dean Kamen. With nearly 1,000 employees and 6,000+ patents, it designs and licenses devices in drug delivery, dialysis, mobility, and autonomous robotics to major healthcare partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersManchester, United States
HQ citystring
Manchester
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical device development, drug delivery systems, mobility assistance technology, water purification equipment, autonomous robotics platforms
Industry1 code
PRIMARYCRADAMAK
Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Medical Device Development and Manufacturing
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Medical Device Development & Licensing
TypeLicensing Royalties
Description

DEKA develops medical technologies and licenses them to established healthcare companies. Examples include the Remunity pump licensed to a partner company and the twiist Automated Insulin Delivery System.

dekaresearch.com
2Product Manufacturing & Sales
TypeHardware Sales
Description

Manufacturing and selling medical devices developed in-house, such as infusion systems, dialysis systems, and mobility enhancement products.

dekaresearch.com
3Contract R&D Services
TypeProfessional Services
Description

Research and development contracting services for healthcare innovation, including partnerships with organizations like Baxter and ARMI.

dekaresearch.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1iBOT
Description

iBOT 3000 was released in 2002 as the first stair-climbing wheelchair. The remastered iBOT PMD offers enhanced features and accessibility.

dekaresearch.com
+4 more records
Core offering1 text field

DEKA Research & Development Corp. is a private engineering R&D company that conceives, designs, prototypes, and licenses medical device technologies spanning drug delivery, dialysis, infusion, mobility, prosthetics, water purification, and autonomous robotics. The firm typically commercializes through licensing, OEM partnerships, and exclusive distribution agreements with established manufacturers such as Baxter (Vantive), Mobius Mobility, and 2Kerr, rather than via direct consumer sales. Its portfolio is anchored by more than 6,000 patents and a near-1,000-person staff of engineers, technicians, machinists, and designers in Manchester, New Hampshire.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Established as market leader in renal therapies with Baxter partnership
+1 more record
Product overview1 text field

DEKA Research & Development is a technology development company with over 6,000 patents that creates life-changing medical technologies. The company's product portfolio centers on healthcare innovation including: insulin delivery systems (twiist Automated Insulin Delivery System, Remunity Pump, Subcutaneous Drug Delivery System), dialysis systems (Baxter Amia, Kaguya, HemoCare), mobility solutions (iBOT stair-climbing wheelchairs, LUKE robotic arm), drug administration devices (microneedle applicators, Daisy device), infusion systems (SAFEflow controller), water purification (Slingshot), and autonomous robotics (SENTRY Robot). DEKA also developed notable inventions like the Segway and Coke Freestyle that were spun off as separate ventures. The company operates with a core competency in fluidics and leverages this expertise across multiple product lines from drug delivery to water treatment.

Product and service13 records
1twiist Automated Insulin Delivery System
CategoryDrug delivery systems
Description

Automated insulin delivery system providing precise, continuous insulin dosing for diabetes management; licensed to pharmaceutical partners for commercial distribution.

2Remunity Pump
CategoryDrug delivery systems
Description

Pump system for stable subcutaneous delivery of Remodulin to patients requiring pulmonary arterial hypertension treatment; licensed to a partner for distribution.

3iBOT Mobility System
CategoryMobility and assistive technology
Description

Stair-climbing wheelchair platform with balance and multi-terrain capabilities, originally released as iBOT 3000 in 2002 and remastered as iBOT PMD; distributed through Mobius Mobility and 2Kerr.

4LUKE Robotic Arm
CategoryProsthetics
Description

Advanced robotic prosthetic arm that restores upper-limb function and quality of life for individuals with limb loss.

5Subcutaneous Drug Delivery System
CategoryDrug delivery systems
Description

Small, lightweight, wearable infusion pumps with enhanced delivery accuracy, occlusion detection, and monitoring compatibility for delivering drugs such as insulin and Remodulin.

6Therapeutic Self-Administration / Microneedle Applicator
CategoryDrug delivery systems
Description

Microneedle applicator enabling self-administration of therapeutics with virtually no pain, featuring dose-sparing delivery and reduced waste versus conventional needles.

7Baxter Amia Dialysis System
CategoryDialysis systems
Description

User-friendly at-home hemodialysis system developed with Baxter (now Vantive), delivering life-saving renal care to patients worldwide.

8Kaguya Dialysis System
CategoryDialysis systems
Description

Next-generation at-home dialysis system developed in collaboration with Baxter (now Vantive) for renal therapy patients.

9HemoCare Home Hemodialysis Machine
CategoryDialysis systems
Description

Home hemodialysis equipment providing patients with life-saving kidney treatment in a home setting.

10Medical Water / Drug Production System (Caspian)
CategoryWater purification / medical fluidics
Description

On-site medical-grade water production devices for injection using DEKA's fluidics expertise, featuring cloud-based monitoring for real-time data gathering and fleet health assessment.

11SENTRY Robot
CategoryAutonomous robotics
Description

Autonomous robotics platform capable of exploring, patrolling, delivering, traveling various terrains, and tackling curbs; remotely monitored or autonomously operated.

12Slingshot Water Purification Machine
CategoryWater purification
Description

Water purification system leveraging DEKA's Stirling engine technology to address water scarcity by producing clean drinking water.

13Stirling Engine
CategoryPower generation and energy technology
Description

Improved Stirling engine design from DEKA applicable for power generation and refrigeration cycles, also underpinning the Slingshot water purification platform.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

DEKA partnered with West Coast Customs and will.i.am to develop the TRINITY - an all-electric, self-balancing single-passenger 3-wheel micromobility vehicle. DEKA contributed technology expertise and the collaboration debuted at CES in January 2026.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-01-01
Description

NVIDIA provided DGX Spark technology for the TRINITY micromobility vehicle project developed with West Coast Customs and DEKA Research & Development.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

DEKA Research & Development acquired assets from Diatech Diabetes in October 2025, expanding its presence in the diabetes technology market.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

DEKA partnered with Baxter on their first dialysis system, and DEKA's technologies have established themselves as the market leader in renal therapies. User-friendly at-home systems including the Amia and Kaguya deliver life-saving care worldwide. The renal care business is now part of Vantive.

5Mobius Mobility
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Mobius Mobility distributes the iBOT PMD (Personal Mobility Device), DEKA's remastered stair-climbing wheelchair with more features and better accessibility.

dekaresearch.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

2Kerr distributes the iBOT Duo, DEKA's autonomous mobility technology platform.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

DEKA partnered with ARMI to advance the bioeconomy of the United States. Technologies focus on manufacturing of cells, tissues, and organs to usher in a new era of biofabrication.

8will.i.am
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaborated with will.i.am on the TRINITY all-electric micromobility vehicle project that debuted at CES 2026.

dekaresearch.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Stryker's broad medical device portfolio, including surgical instruments, orthopedic implants, and mobility solutions, overlaps with DEKA's surgical instrument development and LUKE Arm prosthetic initiatives as a broad incumbent competitor and potential acquirer.

TypeEmerging player
Description

Ekso Bionics develops robotic exoskeletons and powered mobility aids that overlap with DEKA's iBOT and SENTRY robotics platforms, targeting similar rehabilitation, mobility-impaired, and industrial end markets with partial technology overlap.

TypeBroad incumbent
Description

Baxter's renal-care business (now Vantive) is both DEKA's primary dialysis distribution partner and a broad incumbent in the same home dialysis and infusion markets where DEKA's Amia, Kaguya, and HemoCare systems compete.

TypeDirect peer
Description

Insulet's Omnipod automated insulin delivery system competes directly with DEKA's twiist AID platform in the patch-pump diabetes market, serving the same patient and provider base with a similar wearable drug-delivery value proposition.

TypeBroad incumbent
Description

Medtronic operates across the same drug-delivery, diabetes (MiniMed), and surgical instrument categories that DEKA serves, and competes head-to-head in automated insulin delivery while also being a potential partner for licensing DEKA IP.

TypeBroad incumbent
Description

Edwards is a leader in cardiac devices and structural heart products, comparable to DEKA's cardiac stent development; both target the cardiovascular device space with regulated, IP-driven products sold to hospitals and specialists.

7Mobius Mobility
TypeDirect peer
Description

Mobius distributes DEKA's iBOT PMD stair-climbing wheelchair; it is also a peer in advanced powered mobility devices for complex rehabilitation, sharing the same end users and clinical buyer profile.

TypeDirect peer
Description

Dexcom's continuous glucose monitors pair with and compete for interface integration with DEKA's twiist AID, making it a direct diabetes-ecosystem peer with overlapping patient, provider, and payer relationships.

9Abbott
TypeBroad incumbent
Description

Abbott's FreeStyle Libre CGM franchise and diabetes care business directly overlaps with DEKA's insulin delivery and monitoring offerings, and Abbott also operates broadly in medical devices and diagnostics where DEKA competes or partners.

TypeDirect peer
Description

Tandem's t:slim X2 insulin pump is a direct competitor to DEKA's twiist system, both targeting Type 1 diabetes patients with automated insulin delivery integrated to CGMs and using a similar B2B2C commercial motion.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DEKA Research & Development

Medical Device Development and Manufacturingdekaresearch.com

DEKA Research & Development is a privately held, founder-led medical technology developer founded in 1982 by Dean Kamen. With nearly 1,000 employees and 6,000+ patents, it designs and licenses devices in drug delivery, dialysis, mobility, and autonomous robotics to major healthcare partners.

What DEKA Research & Development does

DEKA Research & Development Corp. is a privately held, founder-led medical technology development company founded in 1982 by inventor Dean Kamen and headquartered in Manchester, New Hampshire. The company employs nearly 1,000 engineers, technicians, machinists, and designers who develop life-changing medical devices, with a portfolio exceeding 6,000 patents. Its core technical competency is fluidics, which it applies across infusion systems, subcutaneous drug delivery pumps, and on-site medical-grade water production.

DEKA's product portfolio spans multiple medical domains: drug delivery (twiist Automated Insulin Delivery System, Remunity pump for Remodulin, microneedle applicators, SAFEflow infusion controller), home dialysis systems (Amia, Kaguya, HemoCare), mobility solutions (iBOT 3000 and iBOT PMD stair-climbing wheelchairs, LUKE robotic arm), water purification (Slingshot), and autonomous robotics (SENTRY). The company has also spun off notable inventions into separate ventures, including the Segway and the Coke Freestyle beverage dispenser.

DEKA's business model combines three revenue streams: licensing of proprietary technology to established healthcare and pharmaceutical partners, contract R&D services for partners such as Baxter and ARMI, and direct manufacturing of select devices. Distribution is achieved primarily through OEM/embedded partnerships rather than direct sales — most notably with Baxter/Vantive for dialysis, Mobius Mobility and 2Kerr for the iBOT, and pharmaceutical partners for insulin and Remodulin delivery systems. Founder Dean Kamen retains full ownership and operational control of the company, which has remained private since founding.

DEKA Research & Development firmographics

Firmographics
Name
DEKA Research & Development
Legal name
DEKA Research & Development Corp.
Website
https://dekaresearch.com
Company type
Private
Founded year
1982
Operating status
Operating
Headcount range
501–1,000 employees
Short description
DEKA Research & Development is a privately held, founder-led medical technology developer founded in 1982 by Dean Kamen. With nearly 1,000 employees and 6,000+ patents, it designs and licenses devices in drug delivery, dialysis, mobility, and autonomous robotics to major healthcare partners.
Ownership category
akta.pro rank

DEKA Research & Development industry classification

Industry
Product category
Medical Device Development and Manufacturing
NAICS
Surgical and Medical Instrument Manufacturing (339112), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYCRADAMAK
Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)

Keywords

  • Medical device development
  • Drug delivery systems
  • Mobility assistance technology
  • Water purification equipment
  • Autonomous robotics platforms

Where DEKA Research & Development is headquartered

Location

Headquarters

HQ city
Manchester
HQ country
United States
HQ region
North America

Offices1 record

Markets served

DEKA Research & Development business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. Medical Device Development & Licensing: DEKA develops medical technologies and licenses them to established healthcare companies. Examples include the Remunity pump licensed to a partner company and the twiist Automated Insulin Delivery System.
  2. Product Manufacturing & Sales: Manufacturing and selling medical devices developed in-house, such as infusion systems, dialysis systems, and mobility enhancement products.
  3. Contract R&D Services: Research and development contracting services for healthcare innovation, including partnerships with organizations like Baxter and ARMI.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels4 records

DEKA Research & Development product offering

Product offering

Core offering

DEKA Research & Development Corp. is a private engineering R&D company that conceives, designs, prototypes, and licenses medical device technologies spanning drug delivery, dialysis, infusion, mobility, prosthetics, water purification, and autonomous robotics. The firm typically commercializes through licensing, OEM partnerships, and exclusive distribution agreements with established manufacturers such as Baxter (Vantive), Mobius Mobility, and 2Kerr, rather than via direct consumer sales. Its portfolio is anchored by more than 6,000 patents and a near-1,000-person staff of engineers, technicians, machinists, and designers in Manchester, New Hampshire.

Product overview

DEKA Research & Development is a technology development company with over 6,000 patents that creates life-changing medical technologies. The company's product portfolio centers on healthcare innovation including: insulin delivery systems (twiist Automated Insulin Delivery System, Remunity Pump, Subcutaneous Drug Delivery System), dialysis systems (Baxter Amia, Kaguya, HemoCare), mobility solutions (iBOT stair-climbing wheelchairs, LUKE robotic arm), drug administration devices (microneedle applicators, Daisy device), infusion systems (SAFEflow controller), water purification (Slingshot), and autonomous robotics (SENTRY Robot). DEKA also developed notable inventions like the Segway and Coke Freestyle that were spun off as separate ventures. The company operates with a core competency in fluidics and leverages this expertise across multiple product lines from drug delivery to water treatment.

Differentiator

Problem solved

Functional benefit

Brands

  • iBOT: iBOT 3000 was released in 2002 as the first stair-climbing wheelchair. The remastered iBOT PMD offers enhanced features and accessibility.
  • Slingshot
  • LUKE Arm
  • Remunity
  • twiist

Products and services

  • twiist Automated Insulin Delivery System Automated insulin delivery system providing precise, continuous insulin dosing for diabetes management; licensed to pharmaceutical partners for commercial distribution.
  • Remunity Pump Pump system for stable subcutaneous delivery of Remodulin to patients requiring pulmonary arterial hypertension treatment; licensed to a partner for distribution.
  • iBOT Mobility System Stair-climbing wheelchair platform with balance and multi-terrain capabilities, originally released as iBOT 3000 in 2002 and remastered as iBOT PMD; distributed through Mobius Mobility and 2Kerr.
  • LUKE Robotic Arm Advanced robotic prosthetic arm that restores upper-limb function and quality of life for individuals with limb loss.
  • Subcutaneous Drug Delivery System Small, lightweight, wearable infusion pumps with enhanced delivery accuracy, occlusion detection, and monitoring compatibility for delivering drugs such as insulin and Remodulin.
  • Therapeutic Self-Administration / Microneedle Applicator Microneedle applicator enabling self-administration of therapeutics with virtually no pain, featuring dose-sparing delivery and reduced waste versus conventional needles.
  • Baxter Amia Dialysis System User-friendly at-home hemodialysis system developed with Baxter (now Vantive), delivering life-saving renal care to patients worldwide.
  • Kaguya Dialysis System Next-generation at-home dialysis system developed in collaboration with Baxter (now Vantive) for renal therapy patients.
  • HemoCare Home Hemodialysis Machine Home hemodialysis equipment providing patients with life-saving kidney treatment in a home setting.
  • Medical Water / Drug Production System (Caspian) On-site medical-grade water production devices for injection using DEKA's fluidics expertise, featuring cloud-based monitoring for real-time data gathering and fleet health assessment.
  • SENTRY Robot Autonomous robotics platform capable of exploring, patrolling, delivering, traveling various terrains, and tackling curbs; remotely monitored or autonomously operated.
  • Slingshot Water Purification Machine Water purification system leveraging DEKA's Stirling engine technology to address water scarcity by producing clean drinking water.
  • Stirling Engine Improved Stirling engine design from DEKA applicable for power generation and refrigeration cycles, also underpinning the Slingshot water purification platform.

Quantifiable outcome

  • Established as market leader in renal therapies with Baxter partnership
  • +1 more outcomes

Companies that use DEKA Research & Development

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

DEKA Research & Development technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature9 records

DEKA Research & Development partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • West Coast CustomscoreStrategic or Co-development Partner · 1 January 2026DEKA partnered with West Coast Customs and will.i.am to develop the TRINITY - an all-electric, self-balancing single-passenger 3-wheel micromobility vehicle. DEKA contributed technology expertise and the collaboration debuted at CES in January 2026.
  • NVIDIAcoreTechnology or Integration · 1 January 2026NVIDIA provided DGX Spark technology for the TRINITY micromobility vehicle project developed with West Coast Customs and DEKA Research & Development.
  • Diatech DiabetesminorStrategic or Co-development Partner · 1 October 2025DEKA Research & Development acquired assets from Diatech Diabetes in October 2025, expanding its presence in the diabetes technology market.
  • Baxter International (Vantive)coreStrategic or Co-development PartnerDEKA partnered with Baxter on their first dialysis system, and DEKA's technologies have established themselves as the market leader in renal therapies. User-friendly at-home systems including the Amia and Kaguya deliver life-saving care worldwide. The renal care business is now part of Vantive.
  • Mobius MobilitycoreChannel Partner/ Reseller/ DistributorMobius Mobility distributes the iBOT PMD (Personal Mobility Device), DEKA's remastered stair-climbing wheelchair with more features and better accessibility.
  • 2KerrcoreChannel Partner/ Reseller/ Distributor2Kerr distributes the iBOT Duo, DEKA's autonomous mobility technology platform.
  • ARMI (Advanced Regenerative Manufacturing Institute)coreStrategic or Co-development PartnerDEKA partnered with ARMI to advance the bioeconomy of the United States. Technologies focus on manufacturing of cells, tissues, and organs to usher in a new era of biofabrication.
  • will.i.amminorStrategic or Co-development PartnerCollaborated with will.i.am on the TRINITY all-electric micromobility vehicle project that debuted at CES 2026.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

DEKA Research & Development competitors and assessment

Company assessment

Broad incumbents

  • Stryker: Stryker's broad medical device portfolio, including surgical instruments, orthopedic implants, and mobility solutions, overlaps with DEKA's surgical instrument development and LUKE Arm prosthetic initiatives as a broad incumbent competitor and potential acquirer.
  • Baxter International (Vantive): Baxter's renal-care business (now Vantive) is both DEKA's primary dialysis distribution partner and a broad incumbent in the same home dialysis and infusion markets where DEKA's Amia, Kaguya, and HemoCare systems compete.
  • Medtronic: Medtronic operates across the same drug-delivery, diabetes (MiniMed), and surgical instrument categories that DEKA serves, and competes head-to-head in automated insulin delivery while also being a potential partner for licensing DEKA IP.
  • Edwards Lifesciences: Edwards is a leader in cardiac devices and structural heart products, comparable to DEKA's cardiac stent development; both target the cardiovascular device space with regulated, IP-driven products sold to hospitals and specialists.
  • Abbott: Abbott's FreeStyle Libre CGM franchise and diabetes care business directly overlaps with DEKA's insulin delivery and monitoring offerings, and Abbott also operates broadly in medical devices and diagnostics where DEKA competes or partners.

Emerging players

  • Ekso Bionics: Ekso Bionics develops robotic exoskeletons and powered mobility aids that overlap with DEKA's iBOT and SENTRY robotics platforms, targeting similar rehabilitation, mobility-impaired, and industrial end markets with partial technology overlap.

Direct peers

  • Insulet: Insulet's Omnipod automated insulin delivery system competes directly with DEKA's twiist AID platform in the patch-pump diabetes market, serving the same patient and provider base with a similar wearable drug-delivery value proposition.
  • Mobius Mobility: Mobius distributes DEKA's iBOT PMD stair-climbing wheelchair; it is also a peer in advanced powered mobility devices for complex rehabilitation, sharing the same end users and clinical buyer profile.
  • Dexcom: Dexcom's continuous glucose monitors pair with and compete for interface integration with DEKA's twiist AID, making it a direct diabetes-ecosystem peer with overlapping patient, provider, and payer relationships.
  • Tandem Diabetes Care: Tandem's t:slim X2 insulin pump is a direct competitor to DEKA's twiist system, both targeting Type 1 diabetes patients with automated insulin delivery integrated to CGMs and using a similar B2B2C commercial motion.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

DEKA Research & Development social profiles

Digital presence

DEKA Research & Development financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DEKA Research & Development leadership team

Management profile

Number of profiles

Profiles4 records

DEKA Research & Development funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DEKA Research & Development M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DEKA Research & Development

What does DEKA Research & Development do?

DEKA Research & Development Corp. is a private engineering R&D company that conceives, designs, prototypes, and licenses medical device technologies spanning drug delivery, dialysis, infusion, mobility, prosthetics, water purification, and autonomous robotics. The firm typically commercializes through licensing, OEM partnerships, and exclusive distribution agreements with established manufacturers such as Baxter (Vantive), Mobius Mobility, and 2Kerr, rather than via direct consumer sales. Its portfolio is anchored by more than 6,000 patents and a near-1,000-person staff of engineers, technicians, machinists, and designers in Manchester, New Hampshire.

Is DEKA Research & Development a public or private company?

DEKA Research & Development is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was DEKA Research & Development founded?

DEKA Research & Development was founded in 1982. It employs 501 to 1,000 people.

Where is DEKA Research & Development based?

DEKA Research & Development is headquartered in Manchester, United States, in the North America region.

How does DEKA Research & Development make money?

Three revenue lines are on record. Medical Device Development & Licensing is the primary driver. The others are product Manufacturing & Sales and contract R&D Services.

Who are DEKA Research & Development's main competitors?

Broad incumbents on record are Stryker, Baxter International (Vantive), Medtronic, Edwards Lifesciences and Abbott. Ekso Bionics is listed as an emerging player. Direct peers are Insulet, Mobius Mobility, Dexcom and Tandem Diabetes Care.

Does DEKA Research & Development have an API?

No public API is recorded for DEKA Research & Development.

What industry is DEKA Research & Development in?

DEKA Research & Development's product category is Medical Device Development and Manufacturing. Its primary akta.pro industry code is CRADAMAK, Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireMicroneedle Flu Vaccine Research Report 2026: $2.67 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FThe microneedle flu vaccine market is projected to grow from $1.66 billion in 2025 to $1.82 billion in 2026, a 10% CAGR, and to $2.67 billion by 2030. Growth is driven by needle phobia, advances in transdermal delivery, and pandemic preparedness, with North America leading and Asia-Pacific fastest-growing.SequelmedtechSequel’s Automated Insulin Delivery: The Future of Diabetes Care is HereSequel Med Tech has introduced the twiist Automated Insulin Delivery system, an FDA-cleared device for people with type 1 diabetes that directly measures insulin volume and utilizes the Tidepool algorithm. The company is collaborating with DEKA Research & Development Corp., founded by inventor Dean Kamen, to advance this technology. Sequel aims to make the therapy more accessible through pharmacy channels.GlobeNewswireEmergex Announces R&D Collaboration with DEKA Research & Development Corp. for Assessment of Emergex’s Immunotherapeutic Candidates with DEKA’s Intradermal Therapeutic ApplicatorEmergex and DEKA agreed to assess compatibility of Emergex's immunotherapeutic candidates with DEKA's Intradermal Therapeutic Applicator. The collaboration includes a preclinical pharmacokinetic study comparing syringe-based microneedle delivery with the applicator. Pending results, the applicator could advance as an administration device for Emergex's pipeline.GlobeNewswireZealand Pharma and DEKA Research & Development Corp. Announce Collaboration Agreement to Advance Development of Infusion Pump to Be Used with Dasiglucagon for Treatment of Congenital Hyperinsulinism (Zealand Pharma and DEKA announced a collaboration to develop a continuous infusion pump for dasiglucagon to treat congenital hyperinsulinism. DEKA will handle pump development and manufacturing, while Zealand will manage clinical development and commercialization. The pump is intended to support dasiglucagon, which is in phase 3 trials for CHI.GlobeNewswireZealand Pharma and DEKA Research & Development Corp. Announce Collaboration Agreement to Advance Development of Infusion Pump to Be Used with Dasiglucagon for Treatment of Congenital Hyperinsulinism (Zealand Pharma and DEKA announced a collaboration to develop a continuous infusion pump for dasiglucagon to treat congenital hyperinsulinism. DEKA will handle pump development and manufacturing, while Zealand will manage clinical development and commercialization. The pump is intended for use with dasiglucagon, which is in phase 3 trials.PR NewswireUnited Therapeutics and DEKA Announce Additional FDA Clearance Related to the Unity Subcutaneous Delivery System for Remodulin®United Therapeutics Corporation and DEKA Research & Development Corp. received an additional FDA 510(k) clearance for the Unity Subcutaneous Delivery System (Remunity™ pump) for Remodulin®, enabling specialty pharmacies to prefilled cassettes with the medication. The system, initially cleared in May 2019 for patient filling, was jointly developed by both companies for continuous subcutaneous delivery of Remodulin to treat pulmonary arterial hypertension. United Therapeutics plans to launch the Remunity system by July 2020, with a future version under development that will include factory-prefilled disposable components.CBS NewsDrugstore chain CVS developing home kidney dialysis deviceCVS Health is testing a home dialysis device designed by DEKA Research & Development, targeting the $35 billion end-stage kidney care market. The company plans a clinical pilot with up to 70 patients at 10 sites, with FDA review expected within 24-36 months. The device aims to improve outcomes for the 100,000 Americans who start dialysis annually.EngadgetDARPA is giving war vets first access to LUKE bionic arms - EngadgetDARPA delivered two LUKE bionic arms to Walter Reed National Military Medical Center for use by veterans, eight years after development began. The arms, developed by Dean Kamen, can understand multiple commands and were tested for tasks like brushing hair and opening locks. DARPA plans further development to connect them directly to users' nervous systems for greater dexterity and sensory experience.SlashGearToyota Is Giving DEKA's iBOT Wheelchair A Second LifeToyota Motor North America partnered with DEKA to develop a new iBOT wheelchair after the original was discontinued in 2009. The iBOT, which can climb stairs and raise riders to 6 feet, cost $25,000 with Medicare covering only $5,000–$6,000. No timetable or target price has been announced.Popular SciencePure Genius: How Dean Kamen’s Invention Could Bring Clean Water To MillionsDean Kamen's Slingshot water purifier, developed with Coca-Cola, can produce over 250,000 liters of clean water annually from any source. Coca-Cola plans to deploy up to 2,000 units by 2015, aiming to provide 500 million liters yearly. Kamen envisions pairing it with a Stirling generator to reach over a billion people.